Menu Search
Equities

Microbix Biosystems Inc

MBXBF:QXE

Microbix Biosystems Inc

Actions
  • Price (USD)0.24
  • Today's Change0.011 / 4.90%
  • Shares traded2.00k
  • 1 Year change+40.06%
  • Beta--
Data delayed at least 15 minutes, as of Nov 11 2024 14:34 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Microbix Biosystems Inc. develops and commercializes biological and technological solutions for human health and wellbeing. It enables the commercialization of diagnostic assays by making a range of critical ingredients and devices for the global diagnostics industry, notably antigens for immunoassays and its laboratory quality assessment products (QAPs) that support clinical lab proficiency testing, enable assay development and validation, or help ensure the quality of clinical diagnostic workflows. Its segments include development, manufacturing and sales of products relating to the medical diagnostics industry, namely antigens as test ingredients, quality assessment products to help ensure the accuracy of test workflows and viral transport medium to enable collection of patient test samples and, and development and commercialization of novel and proprietary products or technologies, such as Kinlytic. Its Kinlytic urokinase is a biologic thrombolytic drug used to treat blood clots.

  • Revenue in CAD (TTM)23.36m
  • Net income in CAD5.08m
  • Incorporated1978
  • Employees69.00
  • Location
    Microbix Biosystems Inc265 Watline AvenueMISSISSAUGA L4Z 1P3CanadaCAN
  • Phone+1 (905) 361-8910
  • Fax+1 (905) 361-8910
  • Websitehttps://microbix.com/
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.